NCI TTC Partners with Maryland Technology Development Corporation

Maryland Technology Development Corporation (TEDCO) and the National Cancer Institute (NCI) Technology Transfer Center (TTC) entered into a Partnership Intermediary Agreement to support their mutual interests: facilitate the development and licensing of NCI technologies and support collaborative opportunities with companies and Maryland educational institutions that commercialize products for public benefit.

NCI TTC facilitates partnerships between external organizations and the research laboratories of the NCI and nine other NIH institutes and centers. TEDCO focuses on supporting innovation that nurtures researchers, entrepreneurs, startups and early-stage companies engaged in bringing innovative ideas to market for the state of Maryland.

The Agreement with TEDCO includes NCI and nine NIH Institutes/Centers:

  • National Institute on Aging (NIA)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • National Institute on Drug Abuse (NIDA)
  • National Eye Institute (NEI)
  • National Institute on Minority Health and Health Disparities (NIMHD)
  • National Center for Complementary and Integrative Health (NCCIH)
  • National Library of Medicine (NLM)
  • NIH Clinical Center (CC)
  • Center for Information Technology (CIT)

NCI TTC supports utilizing federally conceived Intellectual Property as an incentive for technology development and commercialization. NCI-TTC technologies available for licensing and collaboration with industry include: Small molecules

  • Biologics
  • Devices
  • Diagnostics
  • Vaccines
  • Wearable and Digital Health/Health IT
  • Software
  • Research tools

For more information about this partnership, please contact:

Contact Ronald W. Kaese, TEDCO’s Director of Federal Programs, at 410-715-4170 or

To learn more about NCI-TTC technologies available for licensing, contact John D. Hewes, Ph.D. of NCI TTC at or visit: or